| 產(chǎn)品編號 | bs-1311R |
| 英文名稱 | LYVE-1 Rabbit pAb |
| 中文名稱 | 淋巴管內(nèi)皮透明質(zhì)酸受體抗體 |
| 別 名 | LYVE1; lymphalic vessel endotheilial hyaluronan receptor 1; CRSBP 1; CRSBP1; extracellular link domain containing 1; extracellular link domain-containing 1; HAR; hyaluronic acid receptor; Cell surface retention sequence-binding protein 1; CRSBP-1; extracellular link domain-containing 1; Extracellular link domain-containing protein 1; Lymphatic vessel endothelial hyaluronic acid receptor 1; LYVE1_MOUSE; Lymphatic endothelium specific hyaluronan receptor; LYVE 1; LYVE-1; XLKD1. |
 |
Specific References (5) | bs-1311R has been referenced in 5 publications.
[IF=3.3] Merigo et al. Glucose transporter expression in the human colon. (2018) World.J.Gastroenterol. 24:775-793 IHC-P ; Human.
[IF=2.11] Zhang, Chun, et al. "MTDH/AEG-1-based DNA vaccine suppresses metastasis and enhances chemosensitivity to paclitaxel in pelvic lymph node metastasis."Biomedicine & Pharmacotherapy (2015). IHC-P ; Mouse.
[IF=1.935] Hayashi T et al. Characteristics of Leiomyosarcoma: Induction of Hematogenous Metastasis by Isolated Uterine Mesenchymal Tumor Stem-like Cells Anticancer Res. 2020 Mar;40(3):1255-1265. IHC ; human.
[IF=1.68] Sun, Y., et al. "A Reproducible In-vivo Model of Lymphatic Malformation in Rats." Journal of comparative pathology 145.4 (2011): 390-398. IHC-P ; Rat.
[IF=0] Michurina et al. Linagliptin alleviates fatty liver disease in diabeticdb/dbmice. (2016) World.J.Diabetes. 7:534-546 IHC ; Mouse.
|
| 研究領(lǐng)域 | 心血管 細胞生物 免疫學 細胞類型標志物 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse (predicted: Rat) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 32 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞漿 細胞膜 細胞外基質(zhì) |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from mouse LYVE-1 terminus: 231-318/318 <Cytoplasmic> |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The lymphatic vasculature forms a second circulatory system that drains extracellular fluid from the tissues and provides an exclusive environment in which immune cells can encounter and respond to foreign antigen. Recently a number of interesting molecules have been identified that may be exploited as markers for lymphatic endothelium, including the hyaluronan receptor LYVE1, PALE, VEGFR3, podoplanin. LYVE1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE1 molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves. Function: Ligand-specific transporter trafficking between intracellular organelles (TGN) and the plasma membrane. Plays a role in autocrine regulation of cell growth mediated by growth regulators containing cell surface retention sequence binding (CRS). May act as an hyaluronan (HA) transporter, either mediating its uptake for catabolism within lymphatic endothelial cells themselves, or its transport into the lumen of afferent lymphatic vessels for subsequent re-uptake and degradation in lymph nodes. Subunit: Homodimer; disulfide-linked. Interacts with PDGFB and IGFBP3. Forms a transient ternary complex with PDGFB and PDGFRB in TGN. Subcellular Location: Membrane; Single-pass type I membrane protein. Note=Localized to the plasma membrane and in vesicles near extranuclear membranes which may represent trans-Golgi network (TGN) and endosomes/prelysosomeal compartments. Undergoes ligand-dependent internalization and recycling at the cell surface. Post-translational modifications: O-glycosylated. Similarity: Contains 1 Link domain. SWISS: Q8BHC0 Gene ID: 114332 Database links: Entrez Gene: 10894 Human Entrez Gene: 114332 Mouse Omim: 605702 Human SwissProt: Q9Y5Y7 Human SwissProt: Q8BHC0 Mouse Unigee: 246769 Human Unigene: 655332 Human Unigene: 396078 Mouse 淋巴管標志物 LYVE-1是一種特異性氨基葡聚糖透明質(zhì)酸受體，均勻分布在淋巴管的管腔面和基底膜，目前多用于腫瘤淋巴轉(zhuǎn)移方面的研究。 淋巴管內(nèi)皮細胞透明質(zhì)酸受體1（LYVE1)LYVE1是位于淋巴管內(nèi)皮細胞上的含有322個氨基酸殘基的膜蛋白。與CD44糖蛋白同源，均勻分布于淋巴管內(nèi)外腔面，可與細胞外基質(zhì)的葡萄糖胺聚糖透明質(zhì)酸結(jié)合，具有從組織攝取透明質(zhì)酸鹽并轉(zhuǎn)運至淋巴液的作用。 |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Mouse Liver tissue lysates
Lane 2: Mouse Spleen tissue lysates
Lane 3: Human Huvec cell lysates
Lane 4: Human K562 cell lysates
Primary: Anti- LYVE-1 (bs-1311R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 32 kD
Observed band size: 58 kD
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
